-
Talk to Us: info@nidccglobal.org
-
Location: Washington, DC | Abuja, Nigeria
Language:
Everyday Economic News
Health Catalyst to Participate in Upcoming Investor Conference
Health Catalyst, Inc. (Nasdaq: HCAT) announced that its senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference. CEO Ben Albert will be part of a panel discussion on "AI ROI in Healthcare: Real vs Hype Debate" on June 24, 2026, at 3:30 pm ET. The company aims to accelerate measurable improvement for health systems through its healthcare intelligence solutions.
iRhythm Technologies Data Breach Exposes Patient Information in Cardiac Monitoring Systems – June 2024 Cybersecurity Incident Analysis
iRhythm Technologies, a cardiac monitoring device provider, reported a data breach impacting patient information in June 2026. The breach, disclosed via a California DOJ filing, involved unauthorized access to unencrypted personal data such as names, Social Security Numbers, and medical details for over 500 California residents. While specific technical details of the attack are not yet public, the incident underscores significant risks to healthcare data and the regulatory obligations surrounding breach response and notification, leading to recommendations for enhanced security controls and incident response.
IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial Milestone
IDEAYA Biosciences (IDYA) stock is gaining attention after enrolling the first patient in a Phase 1 trial for MTAP-deleted solid tumors. Despite trading at $30.57 and showing recent short-term momentum, its valuation presents a mixed picture: an internal fair value estimate suggests an 81.5% discount, while its 11.9x Price-to-Sales (P/S) ratio appears high compared to industry averages and an estimated fair P/S of 2.7x. The company, currently unprofitable, faces risks related to its losses and future trial outcomes, though its discounted cash flow model suggests a much higher fair value of $165.44.
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Acurx Pharmaceuticals Inc (ACXP) shareholder structure, listing major individual and institutional holders, their proportion of ownership, and changes over time. It shows that individual investors and investment advisors constitute significant shareholder types, alongside institutional holdings which have seen fluctuations in both the number of institutions and shares held.
AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan
A AstraZeneca (AZN) officer, Mani Sharma, received 1 Ordinary Share as a compensation grant under the company’s Share Incentive Plan. This award was valued at $179.75 per share, based on a GBP134.54 price and a GBP1.0000 to $1.3360 conversion rate. Following this transaction, Sharma directly holds 19,263.4659 AstraZeneca Ordinary Shares.
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Kuehn Law, a shareholder litigation law firm, is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for alleged breaches of fiduciary duties by its officers and directors. The investigation stems from a federal securities lawsuit claiming the company failed to disclose FDA concerns regarding its new product candidate, relacorilant, and the material risk of its New Drug Application being rejected. Investors who purchased CORT prior to October 31, 2024, are encouraged to contact Kuehn Law.
Stryker Neptune 3 Waste Management System targets safer, cleaner operating rooms
Stryker's Neptune 3 Waste Management System is designed to improve operating room safety and efficiency by reducing staff exposure to surgical fluids and decreasing turnaround times between procedures. This closed, mobile system replaces traditional fluid canisters, offering an integrated solution that works with existing OR infrastructure. It aims to enhance ergonomics for staff and provides a cleaner environment for high-volume surgical centers.
Ionis Pharmaceuticals director sells $587,920 in stock By Investing.com
Ionis Pharmaceuticals director Spencer R. Berthelsen sold 8,000 shares of the company's stock for $587,920 after exercising stock options. This transaction was part of a Rule 10b5-1 trading plan. The company has also seen positive developments such as its Alzheimer's drug advancing to registrational development and an increased full-year revenue guidance, leading analysts to raise price targets.
Insider Sell: Johanna Mercier Sells 3,000 Shares of Gilead Scien
Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences Inc (GILD), sold 3,000 shares of the company on June 15, 2026. This transaction adds to her total of 136,000 shares sold over the past year with no purchases. Based on a trading price of $123.92 and a GuruFocus Value of $95.88, Gilead Sciences Inc appears significantly overvalued with a price-to-GF-Value ratio of 1.29.